---
document_datetime: 2025-03-19 16:55:20
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/namuscla-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: namuscla-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.3338519
conversion_datetime: 2025-12-25 12:35:39.921548
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Namuscla

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                           | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|-------------------------|-----------|
| IA/0017              | A.7 - Administrative change - Deletion of manufacturing sites                                   | 07/10/2024                          | n/a                                         |                         |           |
| IA/0016/G            | This was an application for a group of variations. B.III.1.b.3 - Submission of a new/updated or | 02/10/2024                          | n/a                                         |                         |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer   |            |            |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0014              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                        | 22/06/2023 | 09/08/2023 |          | Based on the review of data on quality, safety and efficacy, including all variations introduced since the marketing authorisation was granted, the benefit-risk balance of Namuscla in its approved indication(s) (please refer to the Summary of Product Characteristics) remains favourable and therefore the renewal of the marketing authorisation is recommended, subject to the conditions as detailed in Annex II. The renewal is recommended to be granted with unlimited validity. |
| PSUSA/10738 /202212 | Periodic Safety Update EU Single assessment - mexiletine (centrally authorised products only)                                                                                                                                                                                  | 06/07/2023 | n/a        |          | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| IA/0015             | B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer                                                    | 12/05/2023 | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| IB/0012             | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation                                                                                 | 20/02/2023 | 09/08/2023 | Annex II |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| IB/0011             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 29/11/2022   | n/a   |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------------------------|
| PSUSA/10738 /202112 | Periodic Safety Update EU Single assessment - mexiletine (centrally authorised products only)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 07/07/2022   | n/a   | PRAC Recommendation - maintenance |
| IA/0010/G           | This was an application for a group of variations. B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved                                                                                                                                                                                                                                                            | 10/05/2022   | n/a   |                                   |
| IA/0009/G           | This was an application for a group of variations. B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved | 02/05/2022   | n/a   |                                   |

<div style=\"page-break-after: always\"></div>

|                     | manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Deletion of certificates (in case multiple certificates exist per material)   |            |            |                 |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------|
| PSUSA/10738 /202012 | Periodic Safety Update EU Single assessment - mexiletine (centrally authorised products only)                                                                                                                                                                                                                                                                                             | 08/07/2021 | n/a        |                 | PRAC Recommendation - maintenance |
| PSUSA/10738 /202006 | Periodic Safety Update EU Single assessment - mexiletine (centrally authorised products only)                                                                                                                                                                                                                                                                                             | 14/01/2021 | n/a        |                 | PRAC Recommendation - maintenance |
| PSUSA/10738 /201912 | Periodic Safety Update EU Single assessment - mexiletine (centrally authorised products only)                                                                                                                                                                                                                                                                                             | 09/07/2020 | n/a        |                 | PRAC Recommendation - maintenance |
| IB/0005             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                             | 25/06/2020 | n/a        |                 |                                   |
| N/0004              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                          | 21/04/2020 | 13/07/2020 | PL              |                                   |
| PSUSA/10738 /201906 | Periodic Safety Update EU Single assessment - mexiletine (centrally authorised products only)                                                                                                                                                                                                                                                                                             | 16/01/2020 | n/a        |                 | PRAC Recommendation - maintenance |
| IAIN/0001/G         | This was an application for a group of variations. A.7 - Administrative change - Deletion of                                                                                                                                                                                                                                                                                              | 17/07/2019 | 13/07/2020 | Annex II and PL |                                   |

<div style=\"page-break-after: always\"></div>

| manufacturing sites   |
|-----------------------|